Stockreport

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio Journal [Yahoo! Finance]

INmune Bio Inc. - Common stock  (INMB) 
PDF and immunology company, today announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial. The manuscript, titled, “XPro1595, a Selective [Read more]